Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome.
ADVANCE Risk Engine
Blood sugar control
Cardiovascular event
Endoscopic therapy
Lp-PLA2
hsCRP
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
4
1
2020
medline:
15
4
2021
entrez:
4
1
2020
Statut:
ppublish
Résumé
The duodenal-jejunal bypass liner (DJBL) represents a novel endoscopic minimally invasive treatment option for obesity-associated type 2 diabetes (T2D), affecting body weight and metabolic control. Until now, the effects of DJBL on cardiovascular risk have never been investigated. Between 2012 and 2017, 71 patients with T2D and metabolic syndrome (MS) were recruited for implantation of DJBL for 9-12 months. Within DJBL treatment and a follow-up period of 6 months, patients were analysed for dynamics of cardiovascular biomarkers. Overall cardiovascular risk was estimated by the ADVANCE Risk Engine at time of implantation, explantation and 6 months after explantation of DJBL. DJBL-induced weight loss and improvements in blood sugar control were accompanied by significant decreases of the cardiovascular biomarkers high-sensitive CRP, lipoprotein-associated phospholipase A2 and small dense lipoprotein fraction LDL-4 (p = 0.001, p < 0.001 and p = 0.04, respectively). Estimated overall cardiovascular risk decreased significantly after DJBL implantation and remained stable within 6 months after explantation. In addition to beneficial effects of DJBL on weight loss, glycaemic control and lipid parameters in patients with MS, this is the first study that could further reveal significant impact on serological cardiovascular biomarkers and estimated CV risk, suggesting putative protective effects of DJBL on CV outcome.
Sections du résumé
BACKGROUND
The duodenal-jejunal bypass liner (DJBL) represents a novel endoscopic minimally invasive treatment option for obesity-associated type 2 diabetes (T2D), affecting body weight and metabolic control. Until now, the effects of DJBL on cardiovascular risk have never been investigated.
METHODS
Between 2012 and 2017, 71 patients with T2D and metabolic syndrome (MS) were recruited for implantation of DJBL for 9-12 months. Within DJBL treatment and a follow-up period of 6 months, patients were analysed for dynamics of cardiovascular biomarkers. Overall cardiovascular risk was estimated by the ADVANCE Risk Engine at time of implantation, explantation and 6 months after explantation of DJBL.
RESULTS
DJBL-induced weight loss and improvements in blood sugar control were accompanied by significant decreases of the cardiovascular biomarkers high-sensitive CRP, lipoprotein-associated phospholipase A2 and small dense lipoprotein fraction LDL-4 (p = 0.001, p < 0.001 and p = 0.04, respectively). Estimated overall cardiovascular risk decreased significantly after DJBL implantation and remained stable within 6 months after explantation.
CONCLUSIONS
In addition to beneficial effects of DJBL on weight loss, glycaemic control and lipid parameters in patients with MS, this is the first study that could further reveal significant impact on serological cardiovascular biomarkers and estimated CV risk, suggesting putative protective effects of DJBL on CV outcome.
Identifiants
pubmed: 31898040
doi: 10.1007/s11695-019-04324-2
pii: 10.1007/s11695-019-04324-2
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1200-1210Références
Eur J Pharmacol. 2015 Sep 15;763(Pt A):64-74
pubmed: 26001373
Diabetes Technol Ther. 2009 Nov;11(11):725-32
pubmed: 19905889
PLoS One. 2014 Jan 09;9(1):e83393
pubmed: 24416164
Clin Endocrinol (Oxf). 2008 Feb;68(2):213-9
pubmed: 17803693
Cardiovasc J Afr. 2013 Oct-Nov;24(9-10):376-81
pubmed: 24337215
Arterioscler Thromb Vasc Biol. 2014 May;34(5):1069-77
pubmed: 24558110
Ann Surg. 2010 Feb;251(2):236-43
pubmed: 19858703
Diabetes Obes Metab. 2018 Aug;20(8):1868-1877
pubmed: 29569313
Eur J Endocrinol. 2016 Jan;174(1):R19-28
pubmed: 26340972
Gen Comp Endocrinol. 2002 Sep;128(2):149-52
pubmed: 12392688
Diabetes Care. 2018 May;41(5):1106-1115
pubmed: 29678867
Curr Pharm Des. 2014;20(40):6256-69
pubmed: 24953389
J Endocrinol. 2016 Oct;231(1):11-22
pubmed: 27474690
Nutrients. 2013 Mar 18;5(3):928-48
pubmed: 23507795
Clin Lab. 2011;57(9-10):659-67
pubmed: 22029180
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32
pubmed: 20863953
Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):393-8
pubmed: 21450612
Atherosclerosis. 2017 Apr;259:75-82
pubmed: 28327451
Obes Surg. 2018 Oct;28(10):3020-3027
pubmed: 29948870
Diabetes Care. 2014 Oct;37(10):2813-21
pubmed: 25011950
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
Clin Lab. 2017 Nov 1;63(11):1911-1918
pubmed: 29226642
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Amino Acids. 2015 Sep;47(9):1703-13
pubmed: 25929587
Surg Obes Relat Dis. 2018 Jun;14(6):769-779
pubmed: 29650340
N Engl J Med. 2007 Aug 23;357(8):741-52
pubmed: 17715408
J Card Fail. 2014 Dec;20(12):923-30
pubmed: 25230239
JAMA. 2012 Jan 4;307(1):56-65
pubmed: 22215166
Obes Surg. 2018 Aug;28(8):2187-2196
pubmed: 29504053
Metabolism. 2019 Mar;92:206-216
pubmed: 30576688
Surg Endosc. 2017 Jul;31(7):2881-2891
pubmed: 27804045
Curr Pharm Des. 2013;19(21):3827-40
pubmed: 23286437
Surg Obes Relat Dis. 2013 May-Jun;9(3):482-4
pubmed: 23452926
Eur J Prev Cardiol. 2014 Oct;21(10):1242-8
pubmed: 23787794